Explore every episode of the podcast Skin and Joints Podcast

🎙️   World Psoriasis Day Special 
 

This special World Psoriasis Day episode of The Skin and Joints Podcast shines a light on the evolving psoriasis journey—from the first plaque to total skin clearance. Dermatologist Dr. Jessica Asgarpour, now back in her sunny hometown of Calgary, joins us for an honest, hopeful conversation about how far psoriasis care has come—and where it’s headed next.

From coal tar and cumbersome creams to once-every-12-week biologic injections, Dr. Asgarpour unpacks the “treatment ladder” and what really determines when to climb it. Together they explore:

Why World Psoriasis Day (Oct 29) matters for awareness, stigma reduction, and timely re-referral

How to recognize when a patient is undertreated and ready for escalation

The topical-to-systemic continuum—including steroid-free innovations, orals vs. biologics, and the occasional role for IV therapy

Real-world barriers in access and adherence—from referral deserts to needle phobia

Matching therapy to patient lifestyle, comorbidities, and comfort level (“the clinic playbook”)

Why dermatologists today can say, confidently, that there is hope for every patient

It’s part myth-busting, part motivation—a must-listen whether you’re a clinician optimizing care or a patient ready to revisit your treatment options.

After listening to this episode, participants will be able to:

• Describe the modern therapeutic ladder for psoriasis, from topicals and orals to biologics and infusions.
• Identify clinical and quality-of-life criteria that signal the need for treatment escalation.
• Discuss common barriers leading to undertreatment and strategies to enhance patient access and adherence.
• Compare classes of biologic agents (TNF-α, IL-17, IL-23, IL-12/23) and their practical considerations in real-world care.
• Empower patients with evidence-based reassurance about safety, efficacy, and long-term outcomes of advanced therapies.

🩵 World Psoriasis Day is more than awareness—it’s a call to action for clear skin, renewed confidence, and collaborative care.
#WorldPsoriasisDay #SkinAndJointsPodcast #PsoriasisAwareness #Dermatology #Biologics #PatientJourney #ClearSkinAhead

Supported by SUN Pharma.

Board-certified in both Canada and the U.S., Dr. Asgarpour completed medical school at the Cumming School of Medicine and her Dermatology residency at the University of Alberta. She practices medical, surgical, and cosmetic dermatology with a special interest in hidradenitis suppurativa and deroofing surgeries, as well as acne, psoriasis, eczema, skin cancer, and women’s health. She is currently working at the Skin Health and Wellness Centre in Calgary. She is a lecturer at the University of Toronto, a courtesy clinical associate at Women’s College Hospital, and is an active investigator for ongoing clinical trials in inflammatory diseases. She is a board member on the Canadian Hidradenitis Suppurativa foundation.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

Guests: Dr. Chloe Ward & Dr. Natalie Cunningham
Location: 📍 EADV 2025, Paris 🇫🇷

From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. 

Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).

Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. 

We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. 

Throughout: practical pearls and fresh evidence

Learning Objectives

After this episode, participants will be able to:

1. 🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.
2. 🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.
3. 🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.
4. 🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.
5. 🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.
6. 🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.
7. 🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.
8. 🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.
9. 🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance).

Perfect for

• Dermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. 

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. 

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

Guests: Dr. Chloe Ward & Dr. Natalie Cunningham
Location: 📍 EADV 2025, Paris 🇫🇷

From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. 

Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).

Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. 

We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. 

Throughout: practical pearls and fresh evidence

Learning Objectives

After this episode, participants will be able to:

1. 🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.
2. 🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.
3. 🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.
4. 🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.
5. 🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.
6. 🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.
7. 🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.
8. 🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.
9. 🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance).

Perfect for

• Dermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. 

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NS

Dr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. 

ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ON

Chloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker Edition

Chronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK 

Episode Tasting Menu 🍽️:
Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”)

Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE:

1. DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊
2. Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈

What’s on the tasting menu :
• EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸
• Current adolescent CHE care — steroid limits & non-steroidal gaps 
• DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact 
• Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points 
• Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care 
• Wrap — off-label nuance, what to tell parents/teens, what to watch for next

We dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩.
Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍.

Learning objectives 🎯:

1. Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain).
2. Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳.
3. Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉.
4. Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭.
5. Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅.

Practical pearls (AKA Clinic Cheat Codes) :
• Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌.
• Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍.
• Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️.
• Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴.
• Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄.

—
Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance.

#SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDerm

SUPPORTED BY AN IME GRANT FROM LEO PHARMA

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

 PART 2 — Mix, Match & Don’t Backlash: Barrier-first acne care—does clascoterone deliver?🧱✨

🍿 Dermatologist Faculty Dr. Christina + Dr. Angela Law are back, and this time we connect the dots between skin barrier 🛡️, TEWL, and real-world adherence.

In PART 2, we stress-test the skin-barrier data behind clascoterone and translate it into clinic-ready moves. We’ll appraise the evidence (think study duration, split-face designs, surrogate endpoints like TEWL/corneometry), map how vehicle tech → adherence (hydration, irritation, drop-offs), and show you how to build barrier-smart regimens that pair clascoterone with retinoids/benzoyl peroxide without wrecking the barrier. 

What you’ll take back to clinic:
• A clear-eyed evidence appraisal of clascoterone’s barrier story—and the data we still need
• Practical vehicle-driven adherence tips you can use same day
• A plug-and-play layering blueprint (thin→thick, sandwiching, stepwise starts)
• Counseling scripts your patients will actually follow

Learning Objectives 

1. Appraise the evidence: Critically evaluate the study design and limitations of clascoterone skin-barrier data (e.g., duration, split-face methods, surrogate outcomes) and identify what further evidence would strengthen confidence.
2. Link vehicle → adherence: Explain how vehicle technology (hydrating/emollient bases) influences irritation, drop-offs, and overall adherence—and translate this into regimen choices.
3. Design barrier-smart regimens: Construct a layered acne plan that pairs clascoterone with retinoids/BPO while protecting the barrier (e.g., thin→thick sequencing, moisturizer “sandwich,” stepwise starts).
4. Counsel with scripts: Deliver clear, 60-second AM/PM counseling scripts that cover order of application, moisturizer/sunscreen integration, and what to expect for hydration/irritation over the first 1–2 weeks.

#SkinAndJointsPodcast #Acne #Clascoterone #TopicalTherapy #SkinBarrier #TEWL
#LayeringRoutine #Retinoids #BenzoylPeroxide #Adherence #Dermatology #Pharmacy
#PrimaryCare #MedEd #HCPs #EvidenceBasedSkincare #SebumControl #PoreTalk

ABOUT Dr. Christina Han, MD FRCPC  VANCOUVER, BC

Dr. Han is a Canadian and US board-certified dermatologist currently practicing in Vancouver, British Columbia. Having grown up with various skin conditions, she has great compassion and empathy for her patients, young and old, who are suffering from various hair, skin and nail disorders. She received her medical training at the University of British Columbia, Vancouver and completed additional training at Yonsei University, Seoul, in the fields of dermatological and laser surgery and skin cancer treatment. She has served as a consultant for various pharmaceutical companies focused on developing new skin therapeutics and is a regular attendee at local, national and international dermatological conferences.

For Dr. Han, the decision to work with XYON stemmed from a desire to empower patients through education and truly make a difference in the lives of those affected by skin and hair conditions. She is currently holds a position as Medical Director at XYON.

In her spare time, Dr. Han enjoys going for long walks, hiking, traveling and spending time with her three children.

ABOUT Dr. Angela Law, MD, FRCPC  VANCOUVER, BC

Dr. Angela Law is a board certified Dermatologist in both Canada and the United States. She completed her dermatology residency in a joint program at the University of Saskatchewan and Dalhousie University. She is a Clinical Instructor in the Department of Dermatology and Skin Science at UBC, regularly teaching medical students and residents, and runs the Urgent Dermatology Clinic at Mount Saint Joseph’s Hospital. She also has an active dermatology practice in downtown Vancouver.

Dr. Law also runs the Vulvar Dermatology Clinic at Mount Saint Joseph’s Hospital which is an innovative clinic with a focus on Women’s Health within Providence Health Care.

Supported by an Independent medical education grant from Sun Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️  Our PsO Playbook: Brothers on the Fairway, Biologics Experts in the Clinic ⛳️🧬✨

What happens when two Ontario derms  swap the golf course for the Skin and Joints studio? 

You get a rapid-fire, real-world deep dive into bimekizumab for plaque psoriasis—complete with candid golf confessions, myth-busting on intra-class switching, and a candidiasis reality check you can actually use.

Dr. Ron Vender (80 rounds a season 🙌) and Dr. Jensen Yeung (proud caddy and data devotee) unpack their 16-week, multicentre retrospective review of adults with moderate to severe PsO who’d already tangoed with other IL-17 inhibitors. 

Spoiler: 86 % hit IGA 0/1 and PASI 90, while 63 % nailed PASI 100. Not bad for so-called “tough” patients.

Expect quick-hit pearls on why dual IL-17 A + F blockade matters, how to frame the switch and treatment class conversation in 30 seconds, and why starting with your heaviest hitter first-line might be a good real world strategy️‍♀️💡

• Decode the Data 📊
  Translate 16-week real-world outcomes (IGA 0/1, PASI 90/100) into day-to-day decision-making for IL-17–experienced psoriasis patients.
• Master the Switch 🔄
  Compare primary vs secondary non-responders—and justify when intra-class IL-17 switching still makes clinical (and payer) sense.
• Counsel with Confidence 🗣️
  Craft a 30-60-second convo to prep patients to set realistic skin clearance expectations.
• Rethink the Ladder 🪜
  Debate first-line versus “last-resort” positioning the current IL-17 vs IL-23 landscape.
• Plan for Durability 📅
  Identify unanswered questions—1-year persistence, multi-failure cohorts—and how ongoing real-world follow-up could reshape treatment algorithms.

🔔 Hit play, level up your treatment playbook, and maybe even shave a few strokes off your psoriasis management game. #SkinAndJointsPodcast #PsoriasisPearls 🩺

EXCLUSIVE TO THE SKIN AND JOINTS PODCAST 

Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis. He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several global educational steering committees as well as international advisory boards. He has published over 100 peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.

Dr. Jensen Yeung obtained a B.Sc. (Honours) and MD from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring the newest knowledge in the field of melanoma and dermoscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs weekly psoriasis/phototherapy clinic. 

In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in over 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 180 peer-reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award, the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award, and the 2023 University of Toronto Department of Medicine Award for Excellence in Postgraduate Teaching.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️  Before the Referral to Dr. Abdulla: Filling Your Acne 🛒 ‘Shopping Cart’—Rapid-Fire Ingredients & Real-World Care Considerations (Part 3 of 3)

Episode description

While your patient sits on a six-month wait-list for dermatology, their acne isn’t taking a holiday. 

In the finale of our ingredient deep-dive mini-series, Dr. Sonya Abdulla add to the bulging cart: neo-glucosamine 🧴, glycerin 💧, niacinamide ✨, probiotics 🦠, peptides 🧬, and the aisle heroes—salicylic acid, benzoyl peroxide, and retiinol

Dr. Abdulla also tackles a practice gap too many overlook: the act of referral is not a management plan.

Tune in for bite-sized, practical scripts for product layering ➡️🧖‍♀️➡️🌞 and a myth-busting look at the microbiome 🤯

Powered by a rapid-fire Q&A, and (yes) a self-checkout beep 🔊, this episode hands you an expert toolkit 🧰 to keep acne care moving—because ⏱️ timing is everything.

Learning objectives

⏩ – Identify two evidence-based prescription or OTC therapies to start while patients await referral.

🧪 – Compare how neo-glucosamine, glycerin, niacinamide, salicylic acid, benzoyl peroxide & retinol hit the four pillars of acne pathophysiology.

🔍 – Summarize current evidence (and limits) for probiotics & peptides in acne care, guiding realistic patient expectations.

🤝 – List practical tips and resources that keep pharmacists, GPs & dermatologists co-aligned along the acne journey.

#SkinAndJointsPodcast #AcneCare #DermTips #PrimaryCare #PharmacyPearls #SkinBarrier #IngredientDeepDive #StartLowGoSlow #DermEducation #Neutrogena #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

Opinions are for educational purposes only and do not replace individualized medical advice.

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ Skin & Joints Podcast — Acne Aisle Adventure with Dr. Sonya Abdulla (Part 2 of 3) 🎙️

Dr. Sonya Abdulla is back at the mic, and her shopping cart is starting to look like it needs four-wheel drive. This second instalment rockets from benzoyl-peroxide to sulfur’s glow-up (no more rotten-egg vibes), detours into niacinamide’s barrier-boosting superpowers, and lands on why retinol deserves a nightly standing ovation. 🛒💥🧴

Learning Objectives 📚✨

By the end of Part 2, listeners will be able to:

1. Dose & Dispense Like a Pro 
   •  Choose between OTC benzoyl-peroxide and retinol strengths that maximize efficacy while minimizing irritation. 
2. 🧼 Spot-Treat Smarter 
   • Compare sulfur vs. niacinamide vs. hydrocolloid patches for on-demand blemish triage and know when each option is optimally introduced 
3. 🔍 Master the Mixology
   •  o Sequence AM/PM regimens so retinoids and peroxides play nice, and decode proprietary formulas when % labels ghost you. 
4. 🕵️‍♀️ Escalate with Confidence 
   • Recognize red-flags that warrant prescription-strength upgrades or derm referral. 🚑

🔍 Ingredient Sneak Peek — What’s Rolling onto the Conveyor Belt:

• Benzoyl Peroxide: The OG bacteria-slayer
• Sulfur: Acne care’s retro revival
• Niacinamide: The Swiss-army vitamin
• Retinol / Retinaldehyde: Night-shift gene whisperers that keep new breakouts from ever RSVPing.
• Hydrocolloid Patches: Tiny panic rooms for pimples

Catch the full low-down (percentages, pro hacks, and combo tricks) in the episode—your shopping cart will never be the same. 🎧🛒💥

#AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🛒 Skin & Joints Podcast — Acne Aisle Adventure (Part 1 of 3) 🛒
Ready to turn the drug‑store shelf into your acne‑fighting playground? In this episode host‑with‑the‑most Erin Sahota tags in Toronto derm dynamo Dr. Sonia Abdulla for a cart‑cramming romp through OTC land. From prairie roots to downtown Toronto chic, Dr. A spills secrets on why salicylic acid is the Beyoncé of beta‑hydroxy acids, how to stop patients from “more‑is‑more” exfoliation crimes, and where pharmacists now fit in the prescription‑plus‑product relay race. Expect real‑talk on field therapy vs. spot shots, evidence‑based label sleuthing, and the brand‑new “Dr. Abdulla’s Shopping Cart” lightning round—because nothing says skin‑science like a checkout beep. 🎧✨

By the end of Part 1, listeners will be able to:

Decode the Acne Aisle: List the must‑know OTC actives (salicylic acid, benzoyl peroxide, retinoids, azelaic acid) and match them to cleanser, leave‑on, and spot‑treatment roles.

Coach Like a Pro: Craft patient counseling that sets realistic timelines (2–12 weeks), emphasizes whole‑field application, and prevents over‑zealous scrubbing sabotage.

Sync the Derm‑Pharm Duo: Describe how expanded pharmacist prescribing for mild acne can bridge access gaps and how consistent messaging keeps patients on track.

Build a Tiered Toolkit: Assemble product “menus” at multiple price points—because evidence‑based care shouldn’t hinge on a wallet size.

Grab your earbuds, your metaphorical basket, and part‑two‑worthy curiosity—the checkout line is just getting started! #SkinAndJointsPodcast #AcneUnlocked #PharmToDerm 🛒🧴💥

ABOUT Dr. Sonya Abdulla

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ Part 2 – Safety First 🛡️✨

Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:

• Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊
• No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹
• Main watch-out: shingles (herpes zoster) pops more in adults than teens

Dr. Liu’s playbook:

• Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK).
• Vaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins.
• Lab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo.
• Dose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate.

• Summarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns.
• Apply age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation.

#SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧
 

Dermatologist  |  London,  ON

Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. 

Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️PART 1: From Dupilumab to Abrocitinib🩺✨

Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course. 

Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love?

Along the way you’ll hear:

• The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine.
• Why comorbid alopecia or vitiligo might tip you toward a JAK-first strategy.

• Identify the clinical profile of AD patients who fail or can’t tolerate dupilumab and may benefit from switching to a JAK inhibitor.
• Compare real-world efficacy & speed of response between abrocitinib 100 mg vs 200 mg, and craft pragmatic dose-titration plans.
• Integrate patient-reported outcomes (itch, DLQI) and comorbidity considerations into shared decision-making for advanced AD therapy.

#SkinAndJointsPodcast #AAD2025 #AtopicDermatitis #EczemaCare #JAKinhibitors #Dupilumab #Abrocitinib #DermTwitter #MedEd #Podcast 🎧
 

SUPPORTED BY AN IME GRANT FROM PFIZER.

Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Questions Answered: 

• What’s the translational takeaway for dermatologists?🩺
• Do these findings reassure you about dose escalation or reduction?🤔
• 15 mg vs. 30 mg-clinic conundrum solved🏷️

🌴☀️ Sunshine, palm trees, and late-breaking dermatology data!

🎙️💡 In this special live episode of the Skin and Joints Podcast, from the AAD 2025 in sunny Orlando, Florida,  we breakdown the FLEX UP late breaking trial results for upadacitinib for moderate to severe atopic dermatitis with with two leading Canadian dermatologists: Dr. Melinda Gooderham and Dr. Angela Law!

They also share their ultimate “conference flexes” 

We go beyond EASI, spotlighting itch control 🤲, quality of life, and real-world relevance 🏥 for all those asking, “So what does this mean practically?

Together, our experts explore how this flexible dosing study answers a longstanding question:

•  Should you start patients on the 15 mg or 30 mg dose, and can you switch between them for better results?

Hear how this late-breaking data might recalibrate your go-to prescribing assessment and whether it’s time to tweak your approach.

The discussion pokes at the trial’s design, why Week 12 and 24 were selected, the importance of itch reduction, and safety data. 

Dr. Gooderham and Dr. Law also weigh in on how these findings might—or might not—revolutionize current clinical practice.

1. FLEX UP Trial Design & Rationale
   • Grasp how the study was structured to evaluate flexible dosing of upadacitinib at 15 mg and 30 mg.
2. Clinical Efficacy Measures
   • Understand the role of EASI 90, NRS, and quality-of-life metrics in gauging patient outcomes.
3. Real-World Implications
   • Examine how FLEX UP data supports practical dosing choices—starting big or small—and equips you to address patient questions about switching doses.
4. Safety & Tolerability
   • Summarize the key safety findings (including VTE, serious infections, and zoster) and how they align with existing JAK-inhibitor data.
5. Future Directions
   • Recognize the need for longer-term follow-up and additional analyses to further refine flexible dosing strategies and patient selection.

🌞 Grab a comfy pair of sneakers 👟 and a protein bar 🍫 because we’re tackling front-line, day-to-day dilemmas in AD management—once and for all! Expect wit, warmth, and wisdom in this fast-paced chat, complete with palm trees, protein bars, and plenty of pro tips. 

ABOUT DR. MELINDA GOODERHAM

Dermatologist, Peterborough, ON 

Dr. Melinda Gooderham is a well-established dermatologist who serves as medical director at the SKiN Centre for Dermatology and the principal investigator for the SKiN Research Centre. Dr. Gooderham received her MD from the University of Western Ontario in 1999 and then completed her Dermatology residency at the University of Toronto in 2004. Before training in medicine, Dr. Gooderham obtained a Bachelor of Science degree from Queen’s University in Kingston in 1992 and a Master of Science degree from the University of Guelph in 1995. Dr. Gooderham is an Assistant Professor at Queens University and works as a Consultant Physician at the Peterborough Regional Health Centre (PRHC). A fellow of the Royal College of Physicians and Surgeons of Canada, she has investigated over 200 clinical trials focusing on inflammatory skin diseases, including psoriasis and atopic dermatitis. Beyond clinical practice, Dr. Gooderham actively contributes to dermatology publications as an author, reviewer, and associate editor, with authorship of over 200 articles. Her passion for education extends to global audiences through engaging lectures on innovative therapies for skin diseases.

Dr. Angela Law is a board certified Dermatologist in both Canada and the United States. She completed her dermatology residency in a joint program at the University of Saskatchewan and Dalhousie University. She is a Clinical Instructor in the Department of Dermatology and Skin Science at UBC, regularly teaching medical students and residents, and runs the Urgent Dermatology Clinic at Mount Saint Joseph’s Hospital. She also has an active dermatology practice in downtown Vancouver.

Dr. Law also runs the Vulvar Dermatology Clinic at Mount Saint Joseph’s Hospital which is an innovative clinic with a focus on Women’s Health within Providence Health Care.

Episode supported by Abbvie.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧

🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴

Why queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️

🎯 What you’ll learn:

1. 🧭Define “super responder” in CHE via three lenses:
2. 📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals.
3. ⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety.
4. 🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands.
5. 🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds.

🔊 Teaser sound bites

• “Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯
• “Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅

🎙️ Hit play for late-breaker highlights🌴😅

#AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Lights, laughter, and lasers on sebum?! 🤔 Absolutely!

Join us for our first-ever Skin and Joints Podcast episode live at Fall Clinical 2024 in sunny Las Vegas. 

🎰 We’re unveiling our new segment “Cross-Border Talk,” featuring Dr. Zoe Diana Dreyloos (reformed mechanical engineer ✈️ from North Carolina) and Dr. Andrei Medlitsa US-based dermatologist (hello, North Carolina!) and a Canadian colleague (brrr, Calgary!) trade professional pearls and unique perspectives on acne care.

Expect runway-ready insights on:

• The big reveal of Clascoterone cream’s impact on sebum production (yep, they used a “sebum meter!”)
• Brand-new data showing significant improvements in both inflammatory and non-inflammatory acne lesions
• The “golden ticket” to fine dining in Vegas, plus confessions of flight fantasies (hint: not all high-flying action happens at the blackjack table)

If you’re tired of your patients asking, “Doc, how do I zap this shine?”—this is the episode for you. Because (despite the famous saying) what happens in Vegas definitely won’t stay in Vegas this time. Tune in for the scoop on everything from sebum science to top-secret bunker restaurants. 🍸

Episode Learning Objectives

1. Understand the central role of sebum production in acne pathogenesis and how it shapes therapeutic strategies.
2. Evaluate the newly released 12-week clinical data on Clascoterone cream 1%—with measured impact on both inflammatory and non-inflammatory lesions.
3. Discuss the safety and tolerability profile of Clascoterone, including real-world patient adherence considerations.
4. Translate the study’s findings into everyday practice, identifying which acne patients might benefit most from sebum-targeted therapy.
5. Explore future research directions, including combination approaches, longer-term outcomes, and potential applications in severe acne or pore-size reduction.
6. Understand the pivotal role of sebum production in acne pathogenesis and how it shapes therapeutic decisions.
7. Examine the newest 12-week clinical data on Clascoterone cream 1%—including its documented impact on both inflammatory and non-inflammatory acne lesions.
8. Apply practical tips for integrating Clascoterone into real-world regimens, tackling oily skin head-on with confidence.

Get ready to rethink your acne game plan…

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations! 

ABOUT Dr. Zoe Diana Draelos, MD, FAAD

DERMATOLOGIST, HIGH POINT, NORTH CAROLINA

Zoe Diana Draelos, MD, is a research and clinical board-certified dermatologist and a Fellow of the American Academy of Dermatology. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. In 1988, she founded Dermatology Consulting Services, PLLC, to initiate and perform research in aging skin, acne, rosacea, psoriasis, atopic dermatitis, actinic keratoses, eczema, and aesthetic procedures in the cosmetic, OTC drug, and pharmaceutical arenas. Prior to pursuing a medical career, Dr. Draelos completed an undergraduate degree in Mechanical Engineering and was elected a Rhodes Scholar. A member of Sigma Xi research honorary and Alpha Omega Alpha medical honorary, she is author of 14 books including Cosmetics in Dermatology and Hair Cosmetics. She is the editor of Cosmetic Dermatology: Products and Procedures (third edition) and Cosmeceuticals (fourth edition) with translations into 7 languages. She has contributed chapters to 44 textbooks, written 173 posters, served as the principal investigator on 982 studies, written 650 published papers, served on or contributed to 38 journal editorial boards, functioned as the editor-in-chief of the Journal of Cosmetic Dermatology for 10 years, and was a past member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery. She was elected Vice-President of the American Academy of Dermatology. She is recognized as a pioneer in cosmetic dermatology and received a lifetime achievement award from Health Beauty America for her research and the 2008 DermArts award for her contributions to dermatology. In 2010, she received the Albert Kligman Innovation Award and in 2016 she was awarded a Presidential Citation from the American Academy of Dermatology for her research contributions to advance the specialty. She received the prestigious Maison deNavarre award from the Society of Cosmetic Chemists for her contributions to the art and science of cosmetics in 2017. In 2019, she was the inaugural recipient of the Florence Wall Award from the Society of Cosmetics Chemists naming her as the most influential women in cosmetic science.

ABOUT Dr. Andrei Metelitsa, MD, FRCPC, FAAD

DERMATOLOGIST, CALGARY, AB

Dr. Metelitsa is a Board-Certified Dermatologist in both Canada and United States and is currently a Clinical Professor at the University of Calgary's Faculty of Medicine. He graduated from medical school at the University of Alberta, Canada at the age of 23. He further received a 5-year dermatology training at the University of Alberta. After completing his residency, Dr. Metelitsa pursued an additional 1-year fellowship training in Lasers and Cosmetic Surgery in Boston, Massachusetts at SkinCare Physicians under the direction of world-renowned faculty from Harvard and Yale. Dr Metelitsa’s Special Interests include: Botox and Dysport injections, Restylane and Juvederm Injections (filler), CO2 Laser Rejuvenation, Excel V Laser, Skin Cancer, Psoriasis. Dr. Metelitsa is also a primary investigator for clinical trial for new and novel dermatology conditions at Beacon Dermatology.

SUPPORTED BY SUN PHARMA

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hold onto your antioxidants—this episode of the podcast is a full-court press on free radicals! 

When it comes to the science of antioxidants and topical formulations, we have the right person-dermatologist Dr. Mark Lupin debuts as a faculty expert on the podcast to practically decipher what you NEED to know

Also debuting on the podcast, but as a guest co-host, is dermatologist Dr. Vincent Richer who's ready to fire up the hot seat with pharmacist Aaron Sihota to ask  the tough questions.

Don’t miss our RAPID FIRE round where we break down must-know ingredients faster than you can say ‘free radical!’ 🚀🦸

We dust off your old sunscreen routine and show you why slathering on antioxidants might just be your skin’s new secret weapon. Tune in for a fast-paced conversation that hops effortlessly from clinic chairs to concert halls, apples to ferulic acid, and vitamin C to conjugated retinol. Here, myths get busted, fancy science terms get decoded, and you’ll finally learn the ABCs of a top-tier skincare regimen—no sunscreen-shy patients or lost winter gloves required. ☀️🧴🍏

Trust us, this episode is your on-demand playbook reference for practice! 🎧📖

Learning Objectives:

1. Antioxidant Fundamentals: Understand how environmental aggressors cause oxidative stress on the skin and how antioxidants serve as powerful defenders. The latest science on how these mighty molecules supercharge your broad-spectrum sunscreen and reduce UV-induced damage?🌞🔬  ‍🍃
2. Key Ingredients in formulations: Identify evidence-based antioxidant ingredients, learn why they’re paired together, and explore optimal formulation concentrations and pH levels for maximum skin benefits. 🍏🔬
3. Critical Evaluation of Research: Gain tools and strategies to discern credible studies from marketing fluff, ensuring more informed clinical recommendations. 📚🔎
4. Integration into Practice: Discover practical tips for incorporating antioxidants into morning routines, combining them effectively with sunscreens, and managing patient expectations. ⏰✔️
5. Future Directions in Dermatology: Explore the promising frontier of antioxidant research, including their potential to complement medical interventions and the call for standardized validation measures. 🔭🚀

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations! 

ABOUT DR.MARK LUPIN  MD FRCPC DABD 

VICTORIA, BC

Dr. Lupin is a Board-certified Dermatologist, Founder in 1998 of Cosmedica Laser Centre in Victoria, British Columbia and Chief Clinical Officer of MedSpa Partners Inc.He has degrees in Mathematics, Music and Medicine having studied at the University of Toronto, University of British Columbia, Dalhousie University, Indiana University and the University of Southern California. He has special interests in photodermatology and laser medicine, having studied under Professor John Hawk at St John’s Institute of Dermatology, London, England. He is active with research and education, has additional subspecialty training in Neurology and is past President of the Canadian Laser Aesthetic Surgery Society.

As a concert violinist, Dr Lupin has performed as soloist at Carnegie Hall, New York and with major orchestras around the world.  He is Concertmaster of the World Doctors Orchestra (WDO), performing most recently in Australia at the Sydney Opera House, with all proceeds donated to charities. His research interests extend to space medicine and fluid dynamics where he has been active with mathematical modeling for space tools and has developed several patent pending energy efficient devices.

ABOUT Dr. Vincent Richer MD FRCPC 

VANCOUVER, BC

Dr Vincent Richer practices cosmetic dermatology at Pacific Derm Atelier in Vancouver and holds a position as Clinical Assistant Professor at the University of British Columbia’s Department of Dermatology and Skin Science. He trained at Université de Montréal in Medicine and Dermatology and completed a fellowship in Photobiology and Cutaneous Laser Surgery at UBC. He is involved as a subinvestigator in cosmetic clinical trials, has published 35+ peer reviewed scientific articles and is active in undergraduate, graduate and continuing medical education.

EPISODE SUPPORTED BY SKINCEUTICALS AND SKINBETTER SCIENCE.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

Ready to revolutionize your approach to atopic dermatitis?  🤔

Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile.  📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

Learning Objectives:

1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

Epsode supported by an Independent Medical Educational Grant from Lilly.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🚴‍♀️ Biking and the Battle Against Itch! 🎙️

Live from the charming canals of Amsterdam at the EADV 2024 meeting, we sit down with the ever-energetic Dr. Perla Lansang from Toronto! 

🍁 She's ditched cabs and metros to embrace the Dutch biking culture, even bringing her own bike across the pond! 🚲🌍 From navigating streets with more bikes than people 😲 to packing rain ponchos for unpredictable weather ☔, Dr. Lansang shares her love for the city.

🍽️ She's on a mission to find the best delectable mini Dutch pancakes topped with butter and powdered sugar 🥞✨. And while we couldn't coax the secret behind her infamous kale smoothie 🥬🥤, we dive into something even more exciting.

We explore late breaking fresh new data presented at EADV on nemolizumab, the new therapeutic targeting IL-31 that's set to revolutionize atopic dermatitis treatment! What does this new 56-week data from an interim analysis of the phase III ARCADIA long-term extension study mean for your patients?

🧪🔥 Discover how this game-changing drug offers rapid itch relief—some patients feel better in just days! 😮🧖‍♂️

We'll unpack nemolizumab’s long-term efficacy and safety in atopic dermatitis, discuss the stellar safety profile, and delve into how it is poised to transform patient care by improving sleep 😴 and overall quality of life 🌟.

This episode is packed with laughs 😂, insightful clinical pearls 🩺, and a sprinkle of Dutch delight! 🎧🌷

Learning Objectives:

1. Understand the pivotal role of IL-31 in atopic dermatitis and why nemolizumab's targeting of this cytokine is a breakthrough.
2. Review the design, key findings, and clinical significance of the Arcadia 1 and 2 long-term extension data up to 56 weeks.
3. Discuss the rapid efficacy and excellent safety profile of nemolizumab and its impact on itch relief, clearance and patient adherence.
4. Evaluate the clinical implications of integrating nemolizumab into practice and its potential to transform atopic dermatitis management.

ABOUT  Dr. Perla Lansang, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Perla Lansang is a full-time staff dermatologist and associate professor in the Division of Dermatology, University of Toronto where she is the Division Head of Dermatology at Sunnybrook Health Sciences Centre. She is also cross appointed at the Section of Paediatric Dermatology at the Hospital for Sick Children, and the Division of Obstetric Medicine at Sunnybrook Health Sciences Centre.

She completed her medical school and dermatology residency at the University of the Philippines-Philippine General Hospital. Having done fellowships in paediatric dermatology at The Hospital for Sick Children and in advanced medical dermatology at Sunnybrook Health Sciences Centre, Dr. Lansang’s practice is a mixture of pediatric, adolescent, and adult dermatology, with a special focus on psoriasis, atopic dermatitis, cutaneous lymphoma, pregnancy dermatoses, and general medical dermatology. She has a special interest in immune-mediated skin diseases and has extensive clinical and research experience in many areas of immunodermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙 Amsterdam Stories, Delta Force  & A Game-Changing Topical for Chronic Hand Eczema

🎉✨ Melinda Knows Best is BACK! 🚀💥

This time, Dr. Gooderham brings us a heavyweight showdown 🥊 between a new topical superhero 🦸‍♀️ and the reigning oral champ 💊 in the battle against Chronic Hand Eczema!  reporting live from the European Academy of Dermatology and Venereology (EADV) Congress in the beautiful city of Amsterdam! 🇳🇱✨

In this special episode, we’re diving into the Delta Force Trial – a bold study comparing topical delgocitinib to oral alitretinoin for chronic hand eczema  💊🧴

👀 Dr. Gooderham spills the beans on impressive results, rapid relief, and how this new treatment is about to change the game for dermatologists and patients alike. 🎉

Oh, and don’t worry, we didn’t forget to ask  about her Amsterdam adventures! 🌍 Did she run into some famous faces at dinner? 🍽️👀 Tune in for the scoop!

💡 Melinda Knows Best will keep you at the cutting edge of CHE breakthroughs. 👩‍⚕️✨

🎯 Learning Objectives:

1. Explore the Delta Force Trial Findings: Understand the significance of the Delta Force trial comparing topical delgocitinib to oral alitretinoin for chronic hand eczema. 🧴💊
2. Evaluate the Efficacy of Topicals vs Orals for chronic hand eczema: Learn about the early onset of symptom relief with delgocitinib, including i reductions in HEXI scores and patient quality of life improvements. ⏱️📉
3. Identify Key Real-World Implications: Discuss how this new topical treatment can shift the landscape for clinicians and patients, offering rapid, safe relief without the headaches (literally!) of oral therapies. 💡
4.  Dive into secondary endpoints, including itch and pain relief, and how this data compares to other major clinical trials in hand eczema treatment. 📊🔬

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ Skin Joins Podcast Wrap-Up: Sunny Stories & Cool Pools 🌞

We welcome back Dr. Michele Ramien, who graced our podcast last July from the sunny World Congress of Dermatology in Singapore. 🌏 Fast forward, she reflects on dermatology innovation from vibrant city of San Diego! 🌴

Dr. Ramien shares a delightful (and chilly) San Diego story about renting a house wit, a freezing-cold pool, and a group of eager people determined to swim🏊‍♂️❄️

We deep dive into the exciting highlights from the American Academy of Dermatology conference. Dr. Ramien, attending AAD for the first time in a while, reveals fascinating pearls and🩺✨ innovative treatments including the potential for disease remission in young patients, as well as fresh new insights on melasma and post-inflammatory hyperpigmentation in Asian skin 🌟

Dr. Ramien also touches on the importance of adapting treatments for different skin types and the promising future of pediatric dermatology. 👶💡

Learning Objectives:

1. 🌍 Understand the global advancements in dermatology from the AAD conference.
2. 🧴 Learn about innovative treatments for atopic dermatitis, including pediatric applications.
3. 🎨 Explore the management of melasma and post-inflammatory hyperpigmentation in diverse skin types.
4. 🧒 Discover the potential for disease remission in young patients with early and targeted treatments.

Tune in for a blend of personal stories, professional insights, and a sneak peek into the future of dermatological treatments. 📚🔍

Stay tuned, stay informed, and as always, keep your skin happy 🌟🧴

Supported by an IME Grant from Pfizer
 

ABOUT Dr. Michele L. Ramien

Pediatric Dermatologist  |  Calgary

Dr. Michele Ramien is an academic dermatologist based at the Alberta Children’s Hospital, in the foothills of the Rocky Mountains in Calgary, Canada. She has both pediatric and general medical dermatology practices, with a focus on teaching and mentoring the next generations and research interests in eczema management, patient education, and severe cutaneous reactions in children.

Dr. Ramien enjoys volunteer leadership positions as a way to meet colleagues across the country, like-minded and not, who believe that a small group of thoughtful, committed individuals can change and improve dermatology and delivery of care in Canada.  

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ More than Skin Deep Insights with Dr. Lauren Lam!🎙️

👩‍⚕️💬 As we get close to wrapping up our coverage of AAD 2024, get ready as we welcome back Dr. Lauren Lam. We dive deep into her recent experience at the AAD in sunny San Diego. 🌞🏖️

Learning Objectives:

1. 🧠 Understand the practical applications of translational medicine in dermatology, particularly in treating chronic skin conditions.
2. 🛠️ Identify key clinical pearls and advancements in dermatology that can be immediately implemented in practice to improve patient care.

What’s on the agenda for this mini-podcast drop?

1. 🌟 San Diego Stories: From bar hopping in a Japanese-themed spot 🌸🍹 to pelican watching at the pier 🦩📸, Lauren shares her unique experiences and the vibrant cultural mix that San Diego offers.
2. 🔍 Translational Medicine Takeaways: Discover how the latest advancements in bench-to-bedside research are transforming dermatological practices. 🧬🩺
3. 💡 Clinical Pearls Galore:

• Hidradenitis Suppurativa Insights: Understand why de-roofing is essential even with biologics 🩹🔬.
• Alopecia Areata Breakthroughs: Learn about the impact of JAK inhibitors 🧑‍🦲➡️🧑‍🦰.
• Pyoderma Gangrenosum Progress: Hear about the promising results of IL-36 inhibitors in treating this challenging condition 💉🌟.

Join us for a lively episode that blends professional insights with personal anecdotes, and don't miss out on the laughter and wisdom Dr. Lam brings to the table 🎧✨

ABOUT Dr. Lauren Lam 

Dermatologist  |  Calgary

Dr. Lauren Lam is a Canadian & American board-certified dermatologist. She is a native Calgarian who completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings. In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 2🎙️

Description:

In Part 2, dermooncologist Dr. Max Sauder returns to delve deeper into the CASMO algorithm. We navigate the complexities of managing severe cutaneous reactions in patients undergoing radiation. From identifying critical symptoms that necessitate urgent care to understanding the nuances of radiation dermatitis stages and risk factors, this episode is packed with expert insights and practical advice.  We focus on 2 specific areas:

1. Assessment and Severity Evaluation: Guidance on evaluating the severity of skin toxicities, incorporating case studies to illustrate practical approaches.
2. Management Protocols: Exploration of practical management strategies and specific interventions for common skin toxicities, drawing on literature evidence and expert consensus.

Learning Objectives:

Identify Critical Symptoms:

• Recognize severe cutaneous adverse reactions and understand when urgent care is necessary based on symptoms like fever, skin pain, blisters, mucous membrane involvement, and abnormal labs. 🚨

Understand Radiation Dermatitis:

• Differentiate between acute and chronic radiation dermatitis.
• Learn the grading systems (CTCAE and RTOG) and their simplified applications in the CASMO algorithm. 📊

How to Manage Radiation Dermatitis:

• Implement effective treatment strategies for both dry and moist desquamation.
• Understand the role of topical steroids and topical over-the-counter dos and don’ts💊

Recognize Risk Factors:

• Identify the factors that increase the risk of radiation dermatitis, considering the cancer type, radiation modality, and regimen. 🧬
• Learn to manage photosensitivity reactions, particularly with targeted therapies.
• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Photosensitivity Reactions:

• Understand the importance of proactive sun protection and the role of topical treatments. ☀️

Promote Adherence:

• Explore strategies to ensure patient adherence to prescribed skincare and sun protection protocols, emphasizing the importance of these measures in minimizing treatment interruptions. 🛡️

Episode Highlights:

• Danger Zone: Learn to identify those serious skin reactions that need urgent care, stat! 🌡️
• Radiation Dermatitis Deep Dive: Understand the stages and treatment of radiation dermatitis without getting lost in the weeds. 📋
• Risk Factors Unmasked: Get to know the usual suspects behind radiation dermatitis. 🔬
• Photosensitivity Savvy: Protect patients from those sneaky photosensitivity reactions with top-notch tips.  🌞
• Adherence Hacks: Keep patients sticking to their skincare and sun protection routines like glue.  🔄

Join us for a discussion perfect for a quick listen on your commute or work out🎧

REFERENCES AND FURTHER RESOURCES:

1.       The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2.       Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3.       Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4.       Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5.       Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6.       Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🌞🎧Dermatologist Dr.Max Sauder joins us and navigates us through the complexities of modern dermatological care💡

🎙️ My CASMO (Canadian Skin Management in Oncology) Playbook: Part 1🎙️

Get ready for a laugh and learn session as Dr. Jessica Asgarpour takes the co-hosting hot seat! This episode, we’re diving headfirst into the CASMO project with dermo-oncologist Dr. Max Sauder. We’ll decode the CASMO algorithm, tackle the nitty-gritty of managing skin toxicities, and even uncover Dr. Sauder's secret summer plans. Buckle up! 🎢

We're peeling back the layers of the CASMO project, an innovative approach to managing skin toxicities in cancer treatment. Can certain skin toxicities be prevented in patients? Is there a proactive skincare regimen that can be recommended?

1. Introduction to CaSMO and Skin Toxicities in Cancer Treatment: Overview of the significance of managing skin toxicities, introducing the CaSMO algorithm's development and objectives.
2. Prevention Strategies: Detailed discussion on general skincare measures recommended by CaSMO, including the rationale behind the use of cleansers and moisturizers to maintain skin hydration and integrity.

Episode Learning Objectives:

1. Understand the CASMO algorithm and its role in managing skin toxicities associated with cancer treatments.
2. Recognize the importance of a multidisciplinary approach in improving patient outcomes.
3. Identify practical proactive strategies for preventing and managing skin toxicities.
4. Learn about the impact of skin toxicities on patients' quality of life and how to address these issues.
5. Explore the role of various healthcare providers, including oncologists, nurses, and pharmacists, in supporting patients through their cancer journey.

Press play for a dose of dermatological delight 🎙️✨

Episode supported by an IME Grant from LA ROCHE POSAY

REFERENCES AND FURTHER RESOURCES:

1.       The role of skin care in oncology patients: STL-Supp-SkinCareOnc-v2-correction.pdf (skintherapyletter.com)

2.       Canadian general algorithm (cleanse, moisturize, protect):Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients with Oncology Treatment-Related Skin Toxicities (skintherapyletter.com)

3.       Canadian radiotherapy algorithm:Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis (skintherapyletter.com)

4.       Canadian immunotherapy algorithm: CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer (skintherapyletter.com)

5.       Canadian hormonal therapy algorithm: Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients (skintherapyletter.com)

6.       Canadian targeted therapy algorithm:Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction (skintherapyletter.com)

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions. 

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego! 

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema. 

• Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

• Adapting treatment plans for chronic hand eczema.
• Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

• Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

1. Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
2. Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
3. Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist  |  Toronto 

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

References

1. Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🌞 Tight Spaces & Hair-Raising Breakthroughs – Live from AAD San Diego! 🎙️🌴

Join Skin and Joints Podcast AAD Guest Faculty and Vancouver based dermatologist, Dr,Diana Diao, as she navigates the cramped quarters of a historic boutique hotel in the Gaslamp Quarter—tiny rooms, weird noises, and all! 🏨😅

Dr. Diao explore groundbreaking sessions on alopecia areata, revealing innovative treatments and valuable clinical insights that are shaping the future of dermatology. 

 🌟💊Don't miss out on Dr. Diao's top clinical takeaways that could revolutionize treatment approaches for dermatologists everywhere. Whether it's systemic therapies for extensive scalp involvement or tailored treatments for unique patient profiles, this episode is packed with insights that promise to enhance patient care. 

💬 Tune in, transform your approach with pearls that could change your practice overnight! 

🎧✨ #SkinJointsPodcast #DermatologyInDepth

Learning Objectives:

1. Gain Insight into New Treatments for Alopecia Areata: Learn about the latest advancements and clinical trials discussed at AAD, including newly approved treatments and their application in real world practice.
2. Appreciate the Psychosocial Aspects of Dermatological Conditions: Recognize the significant emotional and social challenges faced by patients with alopecia areata and the importance of addressing these in real world practice.
3. Implement Clinical Pearls in Practice: Discover actionable tips and strategies that can be immediately applied to improve patient outcomes.

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 
Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR.  DIANA DIAO FRCPC, FAAD

Dr. Diana Diao is a Dermatologist and a Clinical Instructor in the Department of Dermatology and Skin Science at the University of British Columbia. She is a consultant dermatologist at both Vancouver General Hospital and St. Paul’s Hospital. Dr. Diao practices medical and procedural dermatology, with a special interest in using energy-based modalities such as lasers to treat a variety of skin conditions.

Dr. Diao completed both her Medical Doctorate degree and dermatology residency training at the University of British Columbia, and is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Diao is a mother, a published author, and has presented her work at conferences such as the World Congress of Dermatology and the American Academy of Dermatology meetings. Dr. Diao is also fluent in Mandarin.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego. 

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into s🎙️🌞 An AAD 2024 Coles Notes Deep Dive – Welcome to a potpourri episode of the Skin and Joints Podcast, streaming from the vibrant city of San Diego. 

Join us as we sit down with Guest Faculty dermatologist expert the much-anticipated Dr. Mark Kirchhoff, whose voice is as deep and profound as his insights into dermatology. 🎤💬

Medical Innovations Uncovered:

• Key Sessions from AAD: We traverse the entire meeting with key insights into significant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 

Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.ignificant advancements, focusing on HS, AD, PsO and AA.

• Late Breaker Highlights: An overview of the most cutting-edge studies presented, including potential new therapies and their implications for future treatment protocols including rethinking long term disease remission to the exploration of new and novel therapeutic targets.

Learning Objectives:

• Delve into Dermatological Innovations: Get the latest updates on groundbreaking treatments for HS, AA, AD and PsO as well as other skin conditions from the AAD meeting. 🔬💡
• Discuss Future Directions in Dermatology: Examine the potential shifts in treatment approaches and how they align with current patient needs and future therapeutic strategies. 🌟

Dr. Kirchhoff also reflects on the changing landscape of medical conferences influenced by social media and digital dissemination of knowledge

Join us for a blend of professional insights and personal anecdotes that promise to educate and entertain. Tune in to catch Dr. Kirchhoff’s voice and vision for the future of dermatology! 📚🎧

 #SkinAndJointsPodcast #DermatologyDeepDive #SanDiegoSun 

Episode supported by an IME Grant from Pfizer and Bausch Health.

 

ABOUT DR. MARK KIRCHHOF,MD, PHD, FRCPC, FAAD

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.

Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 40 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🌍✨ Welcome to a US-Canada Acne Dialogue Where we Unpack the Art of Acne Treatment Customization and Master Practical Clinical Pearls.🎙️🍁🇺🇸

🌉🔬Skin and Joints Podcast Faculty Dermatologist duo, Dr.Linda Stein Gold and Dr. Mimi Tran, converge to unravel a MasterClass on the latest in acne management, distilled straight from the AAD with a focus on defining the role and place of a new topical hormonal anti-androgen agent and why all isotretinoin options are not the same 🌞

🎯Learning Objectives:

1. Advances in Acne Care Innovation: Gain practical insights into the newly released AAD acne guidelines, how they should be used for the patient in front of you, straight from one of the Faculty members that helped create it! Dr.Stein Gold deep dives into the critical balance between guideline recommendations and the nuanced needs of individual patients, highlighting the importance of cost considerations, treatment efficacy, and the patient-practitioner partnership in dermatology.
2. Dive into the world of new acne therapies, including the groundbreaking topical androgen receptor blocker and its role in reducing sebum production. A leap forward in topical acne treatment! 🆕💡
3. Beyond the Surface: Learn about the significance of vehicle design in topical medications — a crucial factor for efficacy, tolerability, and patient satisfaction. It's not just what's inside that counts, but how it's delivered. 🚚💊
4. The Isotretinoin Evolution: Explore the latest advancements in isotretinoin formulations that promise enhanced absorption without the need for fatty meals, paving the way for more effective and flexible treatment options. 🍽️➡️💧
5. Empowering Patients: Embrace the power of visual progress tracking with baseline and follow-up photographs, fostering patient engagement and adherence. A picture is worth a thousand words, especially in acne treatment! 📸📈

🌟 Stay tuned

#HealthcareCrossroads #AcneInnovation #USCanadaConnection 🎧💬

EPISODE Supported by  SUN Pharma

Dermatologist, Detroit, MI

Linda Stein Gold, MD, is Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as Division Head of Dermatology at Henry Ford Health System in West Bloomfield, Michigan.

Dr. Stein Gold earned her undergraduate degree at the Wharton School of the University of Pennsylvania and her medical degree from the University Of Pennsylvania School Of Medicine in Philadelphia and completed her residency in dermatology at Henry Ford Hospital in Detroit.

Dr. Stein Gold is very active in clinical research on a variety of dermatologic conditions, including the treatment of chronic plaque-type psoriasis, actinic keratosis, atopic dermatitis, acne vulgaris, seborrheic dermatitis, and rosacea. She has published articles in journals such as the Journal of the American Academy of Dermatology, Cutis, the Journal of Drugs in Dermatology among others. She is a frequent national and international lecturer on acne, rosacea, psoriasis, actinic keratosis, alopecia, viral infections, atopic dermatitis, and fungal infections, at grand rounds and medical society meetings. She is also the treasurer of the National Acne and Rosacea Society and a member of the National Psoriasis Foundation Medical Board.

Dermatologist, Winnipeg, MB

Dr Mimi Tran is a dual board-certified Dermatologist in Canada and the USA. After graduating from medical school at the University of Calgary, she pursued a rigorous Dermatology residency at the University of British Columbia. She has trained in centres across Canada. With her extensive experience from practicing in Vancouver, Dr Tran decided to bring her exceptional skills and expertise back to her hometown of Winnipeg. Dr. Tran practices in both Medical and Cosmetic Dermatology.  She has a particular interest in Skin Cancer, Acne, Eczema, Psoriasis, as well as Cosmetic Dermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🌞🎙️ Live from AAD 2024 in San Diego!🎙️🌞

We're bringing you the freshest insights straight from the sun-kissed halls of the AAD 2024 conference in San Diego. 🌴✨ With the iconic Hard Rock Hotel glittering in the back, we dive deep into the world of acne - and oh boy, do we have some groundbreaking news for you! 🧴💥

🤩 Joining us are our guest Faculty tag team from Toronto who share their pearls of wisdom under the California sun. We're buzzing about the latest in acne attack plans, especially the shiny new AAD guidelines dropped like a hot potato at the end of January. 📜🔍

🧪 From the comforting confirmation of our daily dermatological dos to the intriguing nods towards affordability and access - this episode is packed! 🎉 We navigate through the sea of sessions to spotlight the crème de la crème on acne management. 🚀

1. Understand the 2024 Acne Guidelines: Gain a comprehensive understanding of the new AD acne guidelines released in January 2024, including their recommendations for the management of acne with topical antibiotics, retinoids, benzoyl peroxides, and the strategic use of oral therapies .
2. Discuss the Impact of Drug Pricing: Delve into the discussion around how drug pricing influences the listing of therapies as first, second, or third line in the guidelines, and consider the implications of this from both U.S. and Canadian perspectives.
3. Consider New and Emerging Therapies: Identify and evaluate new and emerging therapies in acne treatment, including the anticipation of new triple combination therapies and the introduction of clascotarone, highlighting their alignment with guideline recommendations for combination therapies
4. Address the BPO Controversy:And just when you thought it couldn't get more exciting, we unboxed the potential of emerging therapies and dived into the benzene buzz surrounding benzoyl peroxide and how to counsel patients on these issues.

Here's to clearer skies and even clearer skin ahead! 🌈👩‍⚕️👨‍⚕️ #AAD2024 #AcneAwareness #DermatologyDeepDive

EPISODE Supported by BAUSCH Health. 

Dermatologist, Toronto, ON 

Dr. Sam Hanna is at the forefront of innovation in cosmetic dermatology and is passionate about improving patient skin health with laser treatments, light treatments, and injectable solutions. Dr. Hanna specializes in achieving natural-looking outcomes by way of a holistic approach to cosmetic medicine. A board certified dermatologist and recognized expert in the use of cosmetic injectables including fillers, neuromodulators and sodium deoxycholate, Dr. Hanna is regularly called upon to share his expertise with physician colleagues in lectures and hands-on-training courses. He also lectures on a variety of issues such as dermatology workforce and skin disease treatments.

Dr. Hanna is the Medical Director at Dermatology On Bloor as well as a Diplomate of the American Board of Dermatology. He travels the world sharing his expertise and insights with the global medical and dermatology community.

Dr. Hanna was one of the first Dermatologists in Canada who was trained and certified to offer the Vacuum-Assisted Cellulite Band Release procedure for treatment of cellulite on the thighs and buttocks.

An active clinical trialist, Dr. Hanna has served as a principal investigator for numerous cosmetic & medical clinical trials with Probity Medical Research.

About Dr.Jessica Asgarpour, MD, FRCPC Dermatologist | Toronto, ON 

Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist.She practices medical, surgical and cosmetic dermatology with a special interest in hidradenitis suppurativa, eczema, acne, psoriasis, and women’s health. She is currently working at Canadian Dermatology Centre and is also a clinical associate at Women’s College Hospital. She is a lecturer at University of Toronto and an active sub-investigator for ongoing clinical trials.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🌞🔍 Photoprotection in Skin of Colour: The Role of Visible Light and New Perspectives on Sun Protection 

Episode Sneak Peek:

• 🤔 Debunking Myths: Think all skin reacts the same under the sun? Think again! We’re tackling 3 big misconceptions about photodamage across the Fitzpatrick Skin Types.

Hot Seat Confessions: Our panel of dermatologist experts faces the heat 🔥, answering  burning questions:

• Is photodamage consistent across all skin colors?
• Can melanin alone ward off the sun’s advances?
• Do broad-spectrum sunscreens offer the ultimate armor against all sunlight villains?

🌿💡Antioxidants: The Hype or Hero? We dissect the buzz around antioxidants in sunscreens – are they just a marketing myth or a must-have in your skincare arsenal?

🌞🧴  And yes, don’t forget your sunscreen, no matter your shade!

Episode Learning Objectives

• Identify and correct misconceptions regarding the significance of photoprotection across different populations with a focus on darker skin phenotypes.
• Understand the detrimental effects of visible light on skin health.
• Explore the function of Reactive Oxygen Species (ROS) and antioxidants in sunscreen formulations.
• Apply tailored photoprotection regimens for individuals of all Fitzpatrick Skin Types (FSTs)

#SkinAndJointsPodcast #ShadesOfBrown #BeyondLabels #SunProtectionForAll

EPISODE Supported by EUCERIN. 

About Dr.Tasneem F. Mohammad, MD FAAD  

Dermatologist, Detroit, MI

Tasneem F. Mohammad, MD FAAD is a Staff Physician in the Henry Ford Health System Department of Dermatology in Detroit, MI where she also completed her residency training and  a photomedicine and pigmentation research fellowship. Her clinical and research interests include photomedicine, vitiligo, and pigmentary disorders. She has served on various committees for the Global Vitiligo Foundation, Skin of Color Society, and American Academy of Dermatology.  

About Dr. Jennifer Beecker MD, FRCPC, CCFP(EM), DABD

Dermatologist, Ottawa, ON

Dr. Jennifer Beecker is a Royal College-certified dermatologist who is fully trained and certified in three separate medical specialties: Dermatology, Emergency Medicine and Family Medicine. In addition, she has earned American board-certification as a dermatologist by the American Board of Dermatology. Dr. Beecker is an active Staff Dermatologist at The Ottawa Hospital and Assistant Professor at the University of Ottawa. The range of conditions in which Dr. Beecker holds expertise includes medical dermatology, skin cancer, as well as cosmetic dermatology.

Dr. Beecker is a national expert in skin cancer detection and prevention. Dr. Beecker founded the Melanoma and Pigmented Lesion Clinic at The Ottawa Hospital academic teaching centre. She is the only dermatologist in Canada using this specialized equipment at a teaching hospital. Dr. Beecker trains medical residents and medical students in this clinic, as well as in general dermatology clinics. She is also Vice-Chair of the Dermatology Examination Committee at the Royal College of Physicians and Surgeons of Canada, which sets and conducts the exam for dermatology residents graduating and attempting to obtain Canadian certification as a dermatologist.

As Research Director for the Division of Dermatology at The Ottawa Hospital and a Clinical Investigator in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI), Dr. Beecker conducts and supervises many research studies, and has multiple publications in the medical literature. She is invited to lecture about dermatology locally, nationally, and internationally, and is frequently interviewed by the media, especially on topics such as sun protection and skin cancer. In 2020, Dr. Beecker was awarded the prestigious “President’s Cup Award” by the Canadian Dermatology Association for the second time having also received this award in 2016. She is now President Elect of the Canadian Dermatology Association.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔍Welcome back to Part 2 of our dialogue with Skin and Joint Podcast EADV Ambassador, Dr.Melinda Gooderham, where we delve deep into the groundbreaking advancements in treating chronic hand eczema, featuring the innovative pivotal trials and their implications for care. 
Are we entering a new era for care for our patients with chronic  hand eczema?

Making her guest hosting debut on the Podcast, Dr. Jessica Asgarpour joins us for PART 2.

🆕Key Highlights we take a look at in PART 2:

Exploring New Agents in Chronic Hand Eczema Treatment (Efficacy Perspectives and Quality of Life Measures):

• Dr. Gooderham offers an in-depth analysis of delgocitinib cream, a new topical for CHE.
• Delta 1 and Delta 2 trials  focus on efficacy and safety 
  • Outcomes in terms of the Hand Eczema Area and Severity Index (HEXI) and DLQI  scores.

 Safety Profile of Topical  JAK inhibitors:

•  Patient Adherence and Formulation Challenges
•  The role of delgocitinib as a non-steroidal option in treating hand eczema.
• Discussion on the evolving landscape of dermatological treatments and patient access to new therapies 
    

Episode supported by an IME Grant from LEO Pharma

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist. She completed her medical school at the Cumming School of Medicine, in Calgary, Alberta, where she was born and raised. She went on to the University of Alberta for her residency training in dermatology, where she acted as co-chief resident from 2019-2020, and was awarded the Dr. Andrew Lin Dermatology Scholar award. She has also been awarded multiple scholarships to conferences to keep her up-to-date with the ever changing medical literature. 

She has published in many peer-reviewed journals, and practices medicine with this same evidence-based approach. She practices medical, surgical and cosmetic dermatology. When she is not practicing dermatology, she enjoys keeping active and loves to run, spin and hike.  

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🐻Got lost in a labyrinth, found a bear, and almost became a rock star! 🐻⛏️

This week’s drop on the Skin and Joints Podcast PART 1 is a wild ride - from mistaking a geology conference for a dermatology one, to navigating Messe’s maze-like corridors. Ever wondered if ‘Messe’ stands for ‘mess’ or ‘maze’?

Join Dr. Melinda Gooderham, our Skin and Joints Podcast EADV Ambassador, as we uncover the hilarious journey at the EADV Berlin.

Making her guest hosting debut on the Podcast, Dr. Jessica Asgarpour joins us to share tales from her world travels and EADV.

Spoiler alert: it involves accidental geology lectures and statue selfies! 🗺️

Tune in for an episode that’s more twisty than our conference’s hallways: 

• EADV 2023  Conference Debrief: Dr. Melinda Gooderham shares her unique insights from the EADV conference in Berlin, adding a layer of global expertise to the conversation.
• Cultural and Culinary Delights: From the historic streets of Berlin to the culinary adventures, the podcast paints a vivid picture of the experiences beyond the conference halls
• Chronic Hand Eczema (CHE) Insights: An enlightening conversation about CHE, a troublesome condition affecting many, characterized by itchiness, pain, and a significant impact on quality of life.  A deep dive into the existing approaches to managing CHE, outlining their limitations and the need for more effective, long-term solutions.
• Breaking News from EADV: A new tool in the toolkit-delgocitinib's promising results in the DELTA 1 and 2 trials for CHE.
   

Other PART 1 Highlights of the Episode:

• Four-Year Triumph with tralokinumab,  data on Nemolizumab for treating pruritus in atopic dermatitis, psoriasis breakthroughs - oral peptides and more, foam home advantage for scalp and body psoriasis and weighty matters in psoriasis treatment

Episode supported by an IME Grant from LEO Pharma

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

Dr. Jessica Asgarpour is a Canadian and American board-certified dermatologist. She completed her medical school at the Cumming School of Medicine, in Calgary, Alberta, where she was born and raised. She went on to the University of Alberta for her residency training in dermatology, where she acted as co-chief resident from 2019-2020, and was awarded the Dr. Andrew Lin Dermatology Scholar award. She has also been awarded multiple scholarships to conferences to keep her up-to-date with the ever changing medical literature. 

She has published in many peer-reviewed journals, and practices medicine with this same evidence-based approach. She practices medical, surgical and cosmetic dermatology. When she is not practicing dermatology, she enjoys keeping active and loves to run, spin and hike.  

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🎙️ Dr. Lauren Lam joins us  LIVE from the World Congress of Dermatology in Singapore! Dive into our Crazy Rich Asians-style adventures, unpack the future of AI in dermatology, and get the inside scoop on the latest was we think about HS (hidradenitis suppurtiva) 💡

• Dive into Dr. Lam's Singaporean escapades! 🇸🇬
• What's the next big thing for HS treatment? 🧐
• How might AI revolutionize medical writing? ✍️
• Bonus: Have you heard of the  Triple Threat yet?

From mirage-like mansions to cutting-edge derm findings, join us for a roller coaster of insights, anecdotes and unscripted, unfiltered (maybe somewhat savage) moments.

Let Dr.  Lam lead you through an unforgettable journey at the crossroads of dermatology, tech, and an unforgettable experience 🌟

EPISODE Supported by Pfizer.
 

ABOUT Dr. Lauren Lam BScH, MD, FRCPC Medical, Surgical & Cosmetic Dermatologist  Calgary,AB

Clinical Lecturer | Division of Dermatology, Department of Medicine | University of Alberta

Dr. Lam is a Canadian board-certified dermatologist. She completed her medical school training at the University of Calgary & her dermatology residency at the University of Alberta. Since graduating, Dr. Lam has become a Clinical Lecturer with the University of Alberta. Her particular passions in dermatology are acne & hidradenitis suppurativa deroofings. 

In addition to her regular practice, she volunteers on overseas medical trips. Her passion for providing care for under-served populations has taken her to Nunavut & rural Fiji. Outside of medicine, Dr. Lam is a proud aunt to 4 dogs, culinary enthusiast & international explorer.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🍫 Our Convo with Dr.Jerry TAN on Acne, Sun, Shades of Brown, and Identity 🌞🎨

🎙✈️ From a surprise detour in Toronto to runway rendezvous at the world’s best shopping airport. Join us for  Dr. Jerry Tan’s deep dive into what's new in the world of acne

🌍✨Skin and Joints Podcast Dermatologist expert Dr.Jerry Tan untangles the intricate threads of identity. What do we say when someone asks about our ethnicity or race in an ever-mixed global landscape??🎨 Sick of the phototype jargon? Dive into a refreshing conversation where we shift from shades of grey to exploring every shade of brown 🎨

🌞🧴  And yes, don’t forget your sunscreen, no matter your shade!

#SkinAndJointsPodcast #WorldCongressOfDermatology #ShadesOfBrown #BeyondLabels #SunProtectionForAll

P.S. Spoiler Alert: Jet engines might be involved. 📍✈️😉

EPISODE Supported by BAUSCH HEALTH.

About Dr. Jerry Tan

Dermatologist, Windsor, ON

Dr. Tan received his medical degree from Queen’s University in Kingston, Ontario and trained in internal medicine at the University of Toronto and in dermatology at University of British Columbia and University of Michigan. His general dermatology and aesthetic dermatology practices are in Windsor Ontario Canada. He conducts clinical trials research at Windsor Clinical Research, a clinical trials site in dermatology. Aside from industry grants, he has received research funding from the Canadian Dermatology Foundation and the National Institutes of Health Research.

Research focus includes acne, acne scars and rosacea. Additional interests include outcome measurements and informed shared decision making in dermatology. 

Dr. Tan chairs the working group on clinical practice guidelines of the Canadian Dermatology Association, the rosacea international consensus group (ROSCO) and the acne core outcomes research network (ACORN). He has been an associate editor of the Journal of the American Academy of Dermatology and the British Journal of Dermatology. Over the past 3 decades, Dr. Tan has authored/co-authored more than 100 peer-reviewed publications.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🛍️ Mall Maze Misadventures in Singapore 🛍️

🚨🔄Skin and Joints PodcastFaculty Dr. Melinda Gooderham: Dermatologist by day, unintentional mall explorer by... also day. 😂

Circling for hours, getting acquainted with that same pesky roundabout, and yet always ending up at square one – all within a stone’s throw of her hotel.

Could it be strategic design? 🤔 Or perhaps the universe’s way of reminding us that not all shortcuts turn out short. Or maybe just the irresistible allure of Singapore’s shopping havens? 🌆A chic linen suit, anyone? 🌸👗

🎙️ Tune in to hear Dr.Gooderham’s Singapore Story only on the Skin and Joints PodcastLive from the 25th World Congress of Dermatology in Singapore.



Episode supported by an IME Grant from Pfizer

#MallMisadventures#SingaporeStories#DermatologyDiaries#WCD🌏🎧
 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔊🎧 🎙️ What's New in PsO TX: My Real World Experience with Bimekizumab PART 2 🔊🎧

🎙️🩺🔍 Age-defying Dr.Marni Wiseman journeys with us through 22 years in #dermatology, spilling the secrets of revolutionary treatments and today's #psoriasis patient journeys.

🔊🎧 From the evolution of 1st gen biologic therapy to the latest data around Bimekizumab and it's role, we dive into a fresh discussion about Dr.Wiseman's secret sauce when it comes to  treating plaque #psoriasis.

🔊🎧Hear about her initial approach to biologic naïve patients to determine suitability for biologic therapy.

Don't let PART 2 be skin deep; dive right in! 🎙️🩺🔍

In PART 2 we explore: 

•  We deep dive into the real world experience with Dr. Wiseman who brings clarity to the use of Bimekizumab and other molecules in treating moderate to severe plaque psoriasis
• The convenience of Bimekizumab's dosing schedule, its tolerability, and its significant impact on patient-reported outcomes and quality of life. Dr. Wiseman provides a comprehensive view on managing treatment accessibilityand coverage in different Canadian provinces, and  nuances in coverage and criteria for accessing Bimekizumab.
• Dr. Wiseman's approach to baseline workups for patients, emphasizing the importance of screening for comorbidities like psoriatic arthritis and her anticipations for Bimekizumab's expanding indications. She also sheds light on new developments in treating Hidradenitis Suppurativa (HS) with Bimekizumab, based on recent clinical trial data.

 Join us for a masterclass in understanding and managing psoriasis with Dr. Marni Wiseman on the  podcast.

🎙️Spoiler alert: Not all IL-17 inhibitors are created equal! And if you're itching (pun intended) to learn about that one Bimekizumab side effect everyone's talking about and the real world experience, tune in!  

#DermTalks #Derm #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks  #OptimizedOutcomes #DermDeepDive 

Only on the Skin and Joints Podcast !
 

▶️Episode supported by UCB.
 

ABOUT Dr.Marni Wiseman MD FRCPC

Dr. Marni Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology in the Faculty of Medicine at the University of Manitoba, Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY where she is involved in a general dermatology practice.

Dr. Wiseman’s areas of interest include psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and aesthetic dermatology. She actively participates in clinical trials through Wiseman Dermatology Research, where she has participated in over a hundred clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.

Her community commitments are extensive and include involvement with the Canadian Dermatology Association as Provincial Director of the National Sun Awareness Program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman does regular outreach skin cancer screening clinics in rural locations of Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔊🎧 🎙️ Missing Efficiency in Your Dermatology Clinic: A Dive into Lean Sigma Six with Dr. Perry Grewal PART 2🔊🎧

Dr.Perry Grewal drops in to join us on the Skin and Joints Podcast.

Ever find yourself wading through a sea of paperwork, wondering if your clinic's operations could be mistaken for a confetti cannon explosion? 

Dr.Grewal shares concrete examples from his dermatology practice. Key insights include the need to reduce patient motion, streamline the role of nursing staff, and enhance biopsy organization. 

🎉🙈 This week on 'Clinic Chronicles', we're unpacking the magic of Lean Six Sigma - not just a snazzy buzzword but a transformative approach!

Here's the breakdown: 

1️⃣ Define - No more aimless wandering. Set those clear, crisp goals! 

2️⃣ Measure - Count what counts. Metrics matter, folks! 

3️⃣ Analyze - Spot the bumps and glitches in your clinic matrix. 

4️⃣ Improve - Unleash innovative tweaks that'll make your processes smoother than a latte from your favorite barista. 

 5️⃣ Control - Keep that awesomeness going, like an encore at a rock concert!

We're peeling back the layers of 'business as usual' and diving deep into a system that could have your clinic humming like a well-tuned orchestra. 🎶

So, tune in, and let's streamline your clinic game. And remember, a lean clinic isn’t about dieting—it's about dynamic processes! 💼🚀 #ClinicChronicles #LeanIntoIt

In PART 2 we deep dive:

Areas of Concern in Dermatology Workflow:

1. Motion: Minimizing unnecessary movement – from searching for patient records to walking between rooms.
2. Defects: Reducing errors like wrong medication or missed appointments.
3. Overprocessing: Avoiding repetitive tasks.
4. Transportation: Efficient movement of patients, medications, and equipment.
5. Waiting: Reducing patient and staff wait times.

Beyond these, we chat about the age-old problem of "one more question" from patients, suggesting the use of cheat sheets for frequently asked questions. This episode is a masterclass on evaluating and testing hypotheses in real-world scenarios, with a focus on continuous improvement for enhanced patient care and overall clinic efficiency.

Whether you’re in the field of dermatology or looking to optimize any workflow, this episode offers valuable learnings!

#DermTalks #EfficiencyInHealthcare #PharmacyLife #LeanSigmaSixHealth #DermWorkflow #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks  #PracticeReflections #FromThePharmacyToTheClinic #OptimizedOutcomes #DermDeepDive 

Only on the Skin and Joints Podcast !
 

▶️Episode supported by Novartis.
 

ABOUT Dr. Parbeer S. Grewal MD FRCPC FAAD

Medical Director of Rejuvenation Dermatology and Aesthetics Downtown Edmonton

Associate Clinical Professor, University of Alberta, Division of Dermatology

Dr. Grewal is an Associate Clinical Professor within the Faculty of Medicine, Division of Dermatology, at the University of Alberta. He is the Medical Director of Dermatology and Clinical Research Trials at Rejuvenation Dermatology and Aesthetics Downtown Edmonton. He is also a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital, and the Misericordia Hospital. Dr. Grewal has participated in over 80 clinical research trials and has published many journal articles and book chapters in Dermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔊🎧 🎙️ What's New in PsO TX: My Real World Experience with Bimekizumab 🔊🎧

🎙️🩺🔍 Age-defying Dr.Marni Wiseman journeys with us through 22 years in #dermatology, spilling the secrets of revolutionary treatments and today's #psoriasis patient journeys.

🔊🎧 From the evolution of 1st gen biologic therapy to the latest data around Bimekizumab and it's role, we dive into a fresh discussion about Dr.Wiseman's secret sauce when it comes to  treating plaque #psoriasis.

🔊🎧Hear about her initial approach to biologic naïve patients to determine suitability for biologic therapy.

Don't let PART 1 be skin deep; dive right in! 🎙️🩺🔍

In PART 1 we explore:

•  Bimekizumab, a new addition to the IL-17 inhibitor family, a humanized IgG1 antibody that binds both IL-17A and IL-17F.
• Clinical trial insights: Significant and clinically meaningful improvements over various comparators in pivotal studies such as BE VIVID, BE READY, BE SURE, and more. We look at efficacy when compared to other biologics like placebo, ustekinumab, adalimumab, and secukinumab
• Does real-world practice experience align with clinical trials?   IL 17 inhibitors, especially bimekizumab, are associated with fungal infections or oral candidiasis: what you need to know about management and if it really is an issue in practice

🎙️Spoiler alert: Not all IL-17 inhibitors are created equal! And if you're itching (pun intended) to learn about that one Bimekizumab side effect everyone's talking about and the real world experience, tune in!  

#DermTalks #Derm #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks  #OptimizedOutcomes #DermDeepDive 

Only on the Skin and Joints Podcast !
 

▶️Episode supported by UCB.
 

ABOUT Dr.Marni Wiseman MD FRCPC

Dr. Marni Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology in the Faculty of Medicine at the University of Manitoba, Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY where she is involved in a general dermatology practice.

Dr. Wiseman’s areas of interest include psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and aesthetic dermatology. She actively participates in clinical trials through Wiseman Dermatology Research, where she has participated in over a hundred clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.

Her community commitments are extensive and include involvement with the Canadian Dermatology Association as Provincial Director of the National Sun Awareness Program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman does regular outreach skin cancer screening clinics in rural locations of Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔊🎧 🎙️ Missing Efficiency in Your Dermatology Clinic: A Dive into Lean Sigma Six with Dr. Perry Grewal PART 1🔊🎧

Dr.Perry Grewal drops in to join us on the Skin and Joints Podcast.

 💅🍿🎥Summer’s hot, but you know what’s hotter? The latest buzz about the new Barbie movie.  If Barbie taught us anything, it's to be unexpected. And the Skin and Joints podcast? Well, it’s right on brand. Hear Dr.Grewal's take.

Dr.Perry Grewal chat's about a novel real world project he lead utilizing Lean Sigma Six - heard of it? This technique, popular in the automotive industry, might just be the salve for healthcare hitches! Can it be applied to a dermatology practice? Let's find out!

In a world where workflows matter, where seconds count, and inefficiencies lurk behind every corner... 🎵 dun dun DUN 🎵... Get ready for an in-depth episode like no other. 

 If you've ever been held hostage by wait times or struggled with workflow in your clinic, this episode is your antidote.

In PART 1 we deep dive:

• Reflections on balancing medical practice and patient care with the business side
• An inside scoop on the objective behind analyzing a dermatologist's workflow and practice.
• Tackling wait times, staff efficiency, and fax machine fiascos!
   

#DermTalks #EfficiencyInHealthcare #PharmacyLife #LeanSigmaSixHealth #DermWorkflow #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks  #PracticeReflections #FromThePharmacyToTheClinic #OptimizedOutcomes #DermDeepDive 

Only on the Skin and Joints Podcast !
 

▶️Episode supported by Novartis.
 

ABOUT Dr. Parbeer S. Grewal MD FRCPC FAAD

Medical Director of Rejuvenation Dermatology and Aesthetics Downtown Edmonton

Associate Clinical Professor, University of Alberta, Division of Dermatology

Dr. Grewal is an Associate Clinical Professor within the Faculty of Medicine, Division of Dermatology, at the University of Alberta. He is the Medical Director of Dermatology and Clinical Research Trials at Rejuvenation Dermatology and Aesthetics Downtown Edmonton. He is also a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital, and the Misericordia Hospital. Dr. Grewal has participated in over 80 clinical research trials and has published many journal articles and book chapters in Dermatology.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎧 BEDTIME STORIES WITH DR.DUTZ.

🎧 "Island Adventures & Lupus Revelations"

🎙️ 🎙️Ever wondered how a tiny island in Singapore shaped its skyline? Or what it's like to bike through a mangrove swamp in the middle of nowhere? How about the breakthroughs in the world of dermatology?

🎧🚴Dive deep into the tropical and historical allure of Singapore's hidden gem, Lau Uben, where city stones tell as Dr. Dutz shares his extraordinary adventures in Singapore's forgotten islands and the latest in dermatological research as we pedal into the intricate world of Lupus and breakthroughs on the horizon. 🚲💉

What's inside:

• Dr. Dutz's thrilling off-the-rail escapade to a lesser-known Singaporean island. 🏝️
• Juicy nuggets from the World Congress: from skin surprises to systemic lupus treatments: what’s new?
• A tease of a revolutionary non-antibody treatment that's turning heads: get the latest buzz on an oral IL-23 inhibitor. Game-changer? 🚀

Plus, you won’t believe which delicious Singaporean experience eluded Dr. Dutz's palate. 

🎧🚀🍜Pack your curiosity (and maybe a snack) - this episode is a rollercoaster of discovery, history, and cutting-edge medicine! 

🌌Tune in. Get enlightened. And maybe a bit of entertainment

#SkinAndJointsPodcast #DrDutzAdventures #SingaporeTales #BedtimeStoriesWithDrDutz

Episode supported by an IME from Pfizer.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Buckle up, globetrotters! 🌏✈️ Journey with our guest, Dr.Michele Ramien, as she hopscotches across continents, from the chilly climes of Calgary to the bustling streets of Singapore.

But this isn’t just any travel tale—it’s a dermatological world tour with a twist!

We delve into a peculiar case of the stubborn palmoplantar keratoderma and how a woodworking tool might just be the dermatologist’s unexpected sidekick! 🛠️ But that’s not where the story ends. Dive in to discover a groundbreaking treatment path. There’s a new player in town. Get ready to be skin-spired!

Trust us, you won’t want to miss a minute. Ready to go full circle?

Only on the Skin and Joints Podcast 

#DermAroundTheWorld #TravelTalesWithATwist #wcd #dermatology #rheumatology🌐🩺.

EPISODE Supported by Pfizer.
 

About Dr. Michele L. Ramien, FRCPC, FAAD  

Dermatologist | Calgary, AB

Dr. Ramien graduated from McGill Medical School in 2008. She then completed Dermatology residency at the University of Toronto and University of Ottawa. Dr. Ramien has been board-certified in Dermatology by the Royal College of Physicians and Surgeons of Canada and the American Board of Dermatology since 2013, with Pediatric Dermatology certification since 2018.

In 2013-2014, she completed a Pediatric Dermatology fellowship at CHU Sainte-Justine, in Montréal, Québec funded by the University of Ottawa Fellowship for New Faculty and the Children’s Hospital of Eastern Ontario’s Popham Fellowship. Dr. Ramien is currently a Clinician-Investigator at the Alberta Children’s Hospital in Calgary, Alberta. Her practice is focused on clinical care of medically or dermatologically complex children.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙 Live from Singapore, it's The Skin and Joints Podcast with Dr. Sonya Abdulla🌍

Dive into this tantalizing episode where Toronto meets the World Congress of Dermatology.

🎧🍁From the multicultural marvels of Singapore to groundbreaking skin-care revelations, get your dose of dermatology discoveries and some unexpected Singapore stories!

🧴💡 Can skin sensitivity be linked to hormonal phases? Ever heard of sarcosinic acid for acne? Will this be the next game-changer in acne treatment? And get ready because regenerative medicine might just change everything.

🧴🔍 Join us for a dermatological detective story, a touch of compounding chemistry, and a hint of skincare scent controversies. Tune in to hear all about it, and discover other sizzling dermatological updates too. Perfect for anyone wanting to be in-the-know, from the clinic to the cosmetics aisle.

 #ClearSkinClearWay #DermatologyRevealed #CanadianDermatologyDeepDive

EPISODE Supported by L'Oreal Dermatological Beauty.
 

About Dr. Sonya Abdulla MD, FRCPC, FAAD  

Dermatologist | Toronto, ON

Dr. Sonya Abdulla is a double board-certified dermatologist in Canada and the US. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla has an active medical and cosmetic dermatology practice where she is involved in clinical research and teaching. Her clinical interests include acne, rosacea and psoriasis as well as minimally invasive aesthetic procedures including injectables, energy-based devices and laser surgery. Dr. Abdulla is a strong proponent of evidence-based skin care – her opinion and expertise serve as an invaluable resource for patients, peers and media.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙**Skin & Joints Podcast: Live from Singapore!**🎙

Dive into today's episode as Dr. Monica Lee dazzles us with tales from the famed Raffles Hotel, the iconic (and mocktail version of) Singapore Sling, and that jaw-dropping Crazy Rich Asians set. 🍹🎬

• But the juice doesn’t end there! Ever heard of pre-bunking, nudging, or debunking? Discover how these crucial processes combat misinformation in the medical realm, ensuring you're always ahead in the true-fact game. 🚫🤥
• From the secrets of graceful aging across diverse cultures to nitty-gritty anatomical insights for those facial tweaks we all love, Dr. Lee serves a masterclass in understanding and respecting cultural differences in skincare and aesthetics. 🌏💄
• Dermatologists, skincare enthusiasts, and inquisitive minds, get ready for a roller coaster of knowledge, fun facts, and the essence of beauty from every corner of the globe.

Tune in now to be part of the buzz straight from the World Congress of Dermatology 2023. 🎉🎤

And... a little hint: for those battling the myths of atopic dermatitis, Dr. Lee's insights might just be the salve you needed. 🦠🩺

EPISODE Supported by L'Oreal Dermatological Beauty.
 

About Dr.Monica Li MD, FRCPC, FAAD 

Dermatologist  | Vancouver

Monica Li MD, FRCPC, FAAD is a double board-certified, fellowship-trained dermatologist in Canada and the United States, and a Clinical Instructor in the Department of Dermatology & Skin Science at the University of British Columbia. She practices in Vancouver and Surrey. Dr. Li is actively involved with the American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery, has been a spokesperson for the Canadian Dermatology Association, and is author of a number of book chapters and more than 15 peer-reviewed publications. She has been an invited speaker to many national and international conferences, including the most recent past World Congress of Dermatology in Milan. Dr. Li is a regular voice to local and national media on topics in both medical and cosmetic dermatology.
 

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr.Angela Law serves as a special correspondent to the Podcast in Singapore at WCD with the freshest scoops that may change the way you practice when it comes to Acne and Rosacea. 

🎧 Whether you're a skincare savant or just skin-curious, join us on this enlightening WCD mini escapade. 🌟🔊

Dr.Law covers in this Skin and Joints Episode: 

Acne Complexion Chronicles: Navigating acne & rosacea in skin of color isn’t a walk in the park. Beyond primary lesions, there’s the tricky terrain of pigmentation aftermath. Thanks to maestros like Dr.Andrew Alexis, we've got pointers the role of retinoids & azelaic acid against post-inflammatory hyperpigmentation. 🎨💡

Rosacea Revelations: We dive into the world of rosacea treatments and a groundbreaking study that introduces Paroxetine as a potential savior for flushing, Could serotonin 😇 be the key?

Derm Olympics Relay: From the charm of Milan 🍝👠 to the sizzle of Singapore 🌞🍹, the World Congress feels like the grand stage of Dermatology Olympics. On your marks for the next location - Guadalajara or Munich? 🏁🏛️

EPISODE Supported by Bausch Health.
 

About Dr.Angela Law, MD, FRCPC  

Dermatologist  | Vancouver

Dr.Angela Law is a dually certified dermatologist in Canada and the US. She completed her medical school training at the University of British Columbia and was accepted into the joint Dermatology program between the University of Saskatchewan and Dalhousie University. She opened SkinSense Dermatology in Saskatoon after residency and practiced medical and aesthetic dermatology for six years before moving back to Vancouver during the COVID pandemic.  

She is a Clinical Instructor in the Department of Dermatology and Skin Sciences at UBC and sits on the Undergraduate Education Committee in Dermatology. She has a special interest in pediatric and adolescent dermatology but has been trained in all aspects of medical, surgical and cosmetic dermatology. She splits her time between her new medical clinic with a group of seasoned plastic surgeons at Clinic One Three Eight in downtown Vancouver, aesthetics at Dermapure and a Dermatology rapid access clinic at Mount St. Joseph’s Hospital through Providence Health.  

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🩺Dr.Chih-ho Hong shares the intriguing shifts in the treatment landscape for #atopic #dermatitis and how #patient #access is shaping choice.

🌍The World Congress of #Dermatology isn’t just any conference – it really is the Olympics of #Dermatology, and Dr. Hong gives us a peek behind the curtains, tracing his journey from a fresh resident to a podium regular.

Tune in to learn, laugh, and leap into the world of global #AD trends, and hear Dr.Hong's #Singapore #Story 🌍🩺🥇

🎤 Only on the Skin and Joints Podcast
 

EPISODE Supported by an IME Grant from Pfizer
 

ABOUT DR.CHIH-HO HONG

🎧  Dr. Hong is a board certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office based dermatology clinic with a focus on clinical research. He is a Clinical Assistant Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.

Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

 🎉 🙌MINI PODCAST ALERT 🎉 🙌

Join us  as we peel back more layers of the world of dermatology from the heart of WCD 😊🌟🎧

1. My Singapore Story with Dr.Marissa Joseph. Spoiler Alert: There's a tantalizing tease of an Avatar experience that earned brownie points back home, but sorry folks, some things are top secret, and too precious to share. 😉👪🚫📸
2. 🔍Derm Dialogues: Dive deep into sessions attended:

• Highlight: Ultrasonography's magic in HS management. Ready to ride the ultrasound wave? 🌊🔬
• Global chat on atopic dermatitis. Newsflash: It's everywhere, it's tricky, and guess what? Methotrexate still rules the roost. 

• 🌍Equity in Epidermis: 💪🏼💪🏽💪🏾 From racial disparities in diagnosis to the broader impacts of social determinants of health💔, it's a call to arm(amentarium) for all dermatologists.  
• Global Gossip🌐: Healthcare, housing, society - how do they all fit? 🏥🏠👥

🗣️:  Real connections in real-time only on the Skin and Joints Podcast

EPISODE Supported by an IME Grant from Pfizer
 

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨 PART 2! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.
 

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH -of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. And awarded Master CRA in

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.
 

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. 

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 2

🎙️ Tune in to learn how real-world validated tools can revolutionize psoriatic arthritis management, and the potential for enduring change within the dermatology community in PART 2.

🎧 🎉The discussion takes a significant turn as we delve into the complexities that emerge in treatment strategies, especially in the gap between patient referrals and confirmations of diagnosis. The challenge of masking symptoms and determining the right treatment pathway is examined, stressing the importance of understanding both skin and joint conditions in these patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Our dynamic derm-rheum tag team outline compare the practical utility of three different screening tools, in over 50 dermatologists' offices nationwide. Before participating in the project, some dermatologists expressed reservations regarding the perceived time-consuming nature of these tools, the potential for low yield in their population, and a general lack of habitual use or reminders.

• Is this model scalable? What potential barriers stand in its way?  
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️Looking Forward: A critical question remains whether this change is short-term or will translate into long-term behavioral change?

Warm up those ear phones for PART 2! 

Exclusive to the Skin and Joints Podcast.

Episode supported by Novartis.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 1

🎧 🎉We're excited to bring you a first-hand look at a unique model of care that's transforming the lives of psoriatic arthritis patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Be the first to hear the exclusive findings from a trailblazing real world study that the collaboration of over 50 dermatologists. The focus?  The real world use of PsA screening tools and the early detection of psoriatic arthritis that has the potential to revolutionize psoriatic arthritis detection in clinic.

🛎️This episode is an extension of our conversation with Dr. Dutz from last year, where he unveiled the concept of their model and discussed the validated tools used within their practice. Now, they've turned concept into reality, and we're here to unpack it all.

• Is this model scalable? What potential barriers stand in its way?  
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️This episode is more than just a conversation - it's a paradigm shift in the treatment of psoriatic disease and psoriatic arthritis.  

🎙️🎙️Get ready for a world-exclusive reveal as we break the results of this ground-breaking real world study right here on our podcast for the first time.

Episode supported by Novartis.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🔊🎧 BRACE YOUR EARS FOR #ROUND 2 🎧🔊

💡💼🌐 We're thrilled to announce the Skin and Joints Podcast back on the airwaves this week with dynamic #dermatology duo, Dr.Melinda Gooderham and Dr.Geeta Yadav for round 2! 🩺

🌊💡Join us as we sail the "#Psoriasis Sea" as we navigate what you need to know #roflumilast's long-term performance.

🎧Not only are we dropping anchor to delve into what you need to know about its #side effects, but we're also setting up the lighthouse to guide you through their manageability

🧑‍🦱🧭We've got the lifeboat you need: our experts will peel back the layers and offer insights into the #topical cream's effectiveness in #plaquePsO #skin #clearance and #itch #reduction. So, if you've been scratching your head 🧑‍🦱 over #psoriasis, it's time to stop!

𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣? 𝙊𝙧 𝙥𝙤𝙨𝙨𝙞𝙗𝙡𝙮 #𝙧𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙞𝙣 the way we treat #𝙋𝙨𝙤𝙧𝙞𝙖𝙨𝙞𝙨?

🧐🔬🦠 Dr.Geeta Yadav and Dr. Melinda Gooderham are 𝘀𝗼𝗼𝗻 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘀𝗽𝗶𝗹𝗹 𝘁𝗵𝗲 𝗯𝗲𝗮𝗻𝘀  𝗼𝗻 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝘀𝗲𝗲 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆'𝘀 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗻 𝗺𝗮𝗸𝗶𝗻𝗴 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 #𝗽𝗹𝗮𝗾𝘂𝗲𝗣𝘀𝗢 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀

⛵🧭Get ready to set sail with us. This is a conversation that's more than just skin-deep! 🗓️👂

#SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmatters


Only on the Skin and Joints Podcast !

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children. 

▶️Episode supported by Arcutis.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎧 🎉TYK-TOK we’re ready to rock PART 2!

🎙️🎙️ The Skin and Joints Podcast Team continues the conversation with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

 🛎️ Deucravacitinib is finally here! And we're going to be looking at fresh new data that could change your clinical practice.  We also break it down with our expert Faculty so you don't need to :) 

🧵Where do our experts see the overall place  deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world?

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? 

Episode Learning Objectives

• Describe the overall place of deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world
• Examine the clinical efficacy associated with deucravacitinib and other select  biologic and nonbiologic treatments in patients with moderate to severe PsO
• Explore the correlations between responses on clinical and patient reported outcome (PRO) measures from  pooled data from POETYK PSO-1 and PSO-2 pivotal trials
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis  subgroup analyses pooled PSO-1 and PSO-2 data 

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.